The future of HER2-positive breast cancer treatment will be driven by biomarkers — not just HER2 amplification.
This clip explores emerging resistance mechanisms, bispecific antibodies, ADC combinations, PI3K pathway targeting, and why next-generation precision tools are essential as treatment options continue to expand.
Why HER2 Status Alone Is No Longer Enough
You may also like
Recommended Videos
